AI Article Synopsis
- Over the last ten years, new treatments for non-small cell lung cancer adenocarcinoma have emerged based on pharmacogenomics, highlighting the importance of specific genetic tests in everyday clinical practice.
- Key genetic factors to investigate include mutations in the epidermal growth factor receptor, anaplastic lymphoma kinase, and programmed death-ligand 1 to guide therapy choices for cancer patients.
- The case series will discuss the adverse effects experienced by patients treated with the immunotherapies nivolumab and pembrolizumab, along with insights on their treatment and follow-up care.
Article Abstract
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519224 | PMC |
| http://dx.doi.org/10.1016/j.rmcr.2017.07.004 | DOI Listing |
Publication Analysis
Top Keywords
non-small cell
12
cell lung
12
lung cancer
12
adverse effects
8
treatment follow-up
8
effects immunotherapy
4
immunotherapy non-small
4
cancer treatment
4
follow-up three
4
three cases
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!